Patents by Inventor Jean-Luc Puel
Jean-Luc Puel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10966940Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: July 22, 2019Date of Patent: April 6, 2021Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Auris Medical AGInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20200188332Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: July 22, 2019Publication date: June 18, 2020Inventors: Matthieu GUITTON, Jean-Luc PUEL, REMY PUJOL, Jerome RUEL, Jing WANG
-
Publication number: 20190015393Abstract: The present invention relates to a temporary inhibitor of p53 for its use for preventing or reducing cancer relapse in cancer patients.Type: ApplicationFiled: January 18, 2017Publication date: January 17, 2019Inventors: Jean-Luc PUEL, Julien MENARDO, Jing WANG, Nesrine BENKAFADAR
-
Publication number: 20180256514Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: November 15, 2017Publication date: September 13, 2018Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Publication number: 20170224638Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: September 7, 2016Publication date: August 10, 2017Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Patent number: 9463168Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: June 2, 2015Date of Patent: October 11, 2016Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), AURIS MEDICAL AGInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20150265552Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: June 2, 2015Publication date: September 24, 2015Inventors: GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Patent number: 9072662Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: July 31, 2014Date of Patent: July 7, 2015Assignees: Auris Medical AG, Institut National De La Sante et de La Recherche MedicaleInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20150057360Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: July 31, 2014Publication date: February 26, 2015Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Publication number: 20140017172Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: July 9, 2013Publication date: January 16, 2014Inventors: Matthieu GUITTON, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Patent number: 8507525Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: April 1, 2010Date of Patent: August 13, 2013Assignee: Auris Medical AGInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Patent number: 8268866Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.Type: GrantFiled: March 29, 2004Date of Patent: September 18, 2012Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol
-
Publication number: 20100254907Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: April 1, 2010Publication date: October 7, 2010Inventors: Matthieu GUITTON, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20100173874Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.Type: ApplicationFiled: July 30, 2009Publication date: July 8, 2010Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
-
Patent number: 7696197Abstract: The invention concerns the use of a phenothiazine derivative of formula (I), wherein: R represents the hydrogen atom, an alkyl radical, arylalkyl, or —C(O)R?, for preparing a medicine for preventing and/or treating hearing loss.Type: GrantFiled: March 25, 2005Date of Patent: April 13, 2010Assignee: Societe de Conseils de Recherches et d'Applications ScientifiquesInventors: Bernadette Pignol, Jean-Luc Puel, Serge Auvin, Pierre-Entienne Chabrier de Lassauniere, Jing Wang
-
Patent number: 7589110Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.Type: GrantFiled: September 6, 2002Date of Patent: September 15, 2009Assignees: Durect Corporation, InsermInventors: Jean-Luc Puel, Remy Pujol, Yves Christen
-
Publication number: 20080275034Abstract: The invention concerns the use of a phenothiazine derivative of formula (I), wherein: R represents the hydrogen atom, an alkyl radical, arylalkyl, or —C(O)R?, for preparing a medicine for preventing and/or treating hearing loss.Type: ApplicationFiled: March 25, 2005Publication date: November 6, 2008Applicant: Societe de Conseils de Recherches etInventors: Bernadette Pignol, Jean-Luc Puel, Serge Auvin, Pierre-Etierne Chabrier de Lassauniere, Jing Wang
-
Publication number: 20070015727Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.Type: ApplicationFiled: September 6, 2002Publication date: January 18, 2007Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
-
Publication number: 20060063802Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: September 28, 2005Publication date: March 23, 2006Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20050214338Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.Type: ApplicationFiled: March 29, 2004Publication date: September 29, 2005Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol